Clinical Trials CD4 CAR for CD4+ leukemia and lymphoma Study ID#: NCT03829540First In-Human Clinical Trial Targeting CD4 Protein for Aggressive T-cell Leukemia and Lymphoma to be Launched CD4-specific CAR T cells (CD4 CAR T cells) for relapsed/refractory T cell malignancies Study ID#:NCT04162340iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual MeetingAmerican Society of Hematology Annual Meeting: iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations CLL1-CD33 cCAR in patients with relapsed and/or refractory, high risk hematologic malignancies Study ID #: NCT03795779iCell Gene Therapeutics Presents First-in-Human Data of CLL1-CD33 Compound CAR T in Refractory Acute Myeloid LeukemiaCompound CAR T-Cell Therapy Shows Promise for AML BCMA-CD19 cCAR in relapsed and /or refractory multiple myeloma and plasmacytoid lymphoma Study ID#: NCT04162353iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations at 61st American Society of Hematology Annual MeetingAmerican Society of Hematology Annual Meeting: iCell Gene Therapeutics Announces CAR-T Oral and Poster Presentations BCMA-CS1 compound CAR (cCAR) T cells for relapsed/refractory multiple myeloma Study ID#: NCT04156269 CD19 CARvac T cells for patients with relapsed / refractory B cell Malignancies Study ID#: NCT04156243 CD20-CD19 compound CAR (cCAR) T cells for patients with relapsed /refractory B cell malignancies Study ID#: NCT04156178